• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

Raghava.Kashyap@unimelb.edu.au

Credentials


Position
Clinical (Lecturer)
The Sir Peter MacCallum Department of Oncology

Dr Raghava Kashyap

Clinical (Lecturer)
The Sir Peter MacCallum Department of Oncology

90 Scholarly works
0 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial
    DOI: 10.1016/S1470-2045(26)00120-8
  • 2025

    Journal article

    Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis
    DOI: 10.2967/jnumed.125.270804
  • 2025

    Journal article

    Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
    DOI: 10.1016/S1470-2045(25)00559-5
  • 2025

    Journal article

    Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials
    DOI: 10.2967/jnumed.125.269640
  • 2025

    Journal article

    Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours – a single centre experience
    DOI: 10.1007/s00259-025-07235-w
  • 2025

    Journal article

    First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
    DOI: 10.1016/S1470-2045(25)00332-8
  • 2025

    Journal article

    First-in-human results of terbium-161[ 161 Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/II study.
    DOI: 10.1200/jco.2025.43.16_suppl.5010
Raghava Kashyap

RECENT SCHOLARLY WORKS

  • 2025

    Journal article

    Role of neoadjuvant peptide receptor radionuclide therapy in unresectable and metastatic gastro-entero-pancreatic neuroendocrine neoplasms: A scoping review
    DOI: 10.1111/jne.13425
  • 2025

    Journal article

    Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [68Ga]PSMA-11 or [18F]DCFPyL, [18F]FDG, and [177Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus Network
    DOI: 10.2967/jnumed.125.270077
  • 2024

    Journal article

    Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
    DOI: 10.1016/S1470-2045(24)00440-6

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224